Karyopharm Therapeutics (KPTI) Stock Forecast, Price Target & Predictions
KPTI Stock Forecast
Karyopharm Therapeutics stock forecast is as follows: an average price target of $7.33 (represents a 685.64% upside from KPTI’s last price of $0.93) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
KPTI Price Target
The average price target for Karyopharm Therapeutics (KPTI) is $7.33 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $3.00. This represents a potential 685.64% upside from KPTI's last price of $0.93.
KPTI Analyst Ratings
According to 3 Wall Street analysts, Karyopharm Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for KPTI stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Karyopharm Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 10, 2024 | Brian Abrahams | RBC Capital | $3.00 | $0.95 | 215.42% | 221.54% |
| Jan 10, 2023 | - | Leerink Partners | $5.00 | $2.84 | 76.06% | 435.91% |
| Aug 23, 2022 | Collen Kusy | Robert W. Baird | $14.00 | $5.56 | 151.80% | 1400.54% |
| Mar 10, 2022 | Brian Abrahams | RBC Capital | $8.00 | $6.49 | 23.27% | 757.45% |
The latest Karyopharm Therapeutics stock forecast, released on Jun 10, 2024 by Brian Abrahams from RBC Capital, set a price target of $3.00, which represents a 215.42% increase from the stock price at the time of the forecast ($0.95), and a 221.54% increase from KPTI last price ($0.93).
Karyopharm Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $3.00 |
| Last Closing Price | $0.93 | $0.93 | $0.93 |
| Upside/Downside | -100.00% | -100.00% | 221.54% |
In the current month, the average price target of Karyopharm Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Karyopharm Therapeutics's last price of $0.93. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 01, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 10, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jan 10, 2023 | SVB Leerink | Market Perform | Market Perform | Hold |
| Nov 04, 2022 | RBC Capital | Sector Perform | Outperform | Upgrade |
| Mar 10, 2022 | RBC Capital | Sector Perform | Sector Perform | Hold |
Karyopharm Therapeutics's last stock rating was published by H.C. Wainwright on Jul 01, 2024. The company gave KPTI a "Buy" rating, the same as its previous rate.
Karyopharm Therapeutics Financial Forecast
Karyopharm Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $36.01M | $37.58M | $38.70M | $33.58M | $36.15M | $39.68M | $47.67M | $126.27M | $37.69M | $22.60M | $23.26M | $35.10M | $21.33M | $33.51M | $18.14M | $18.10M | $13.15M | $9.49M | $155.00K | $10.00M | $68.00K |
| Avg Forecast | $51.69M | $48.96M | $50.85M | $47.03M | $38.74M | $37.92M | $36.21M | $34.48M | $35.40M | $37.27M | $35.67M | $36.32M | $34.43M | $34.83M | $35.96M | $34.41M | $52.71M | $26.21M | $26.30M | $25.89M | $28.61M | $23.02M | $28.41M | $21.47M | $16.34M | $2.77M | $106.00K | $364.56K | $7.95M | $64.17K |
| High Forecast | $51.69M | $48.96M | $50.85M | $47.03M | $38.74M | $40.34M | $36.21M | $34.48M | $35.40M | $37.27M | $35.67M | $36.32M | $34.43M | $34.83M | $35.96M | $34.41M | $52.71M | $26.21M | $26.30M | $25.89M | $28.61M | $23.02M | $28.41M | $21.47M | $16.34M | $2.77M | $106.00K | $364.56K | $9.54M | $77.00K |
| Low Forecast | $51.69M | $48.96M | $50.85M | $47.03M | $38.74M | $34.00M | $36.21M | $34.48M | $35.40M | $37.27M | $35.67M | $36.32M | $34.43M | $34.83M | $35.96M | $34.41M | $52.71M | $26.21M | $26.30M | $25.89M | $28.61M | $23.02M | $28.41M | $21.47M | $16.34M | $2.77M | $106.00K | $364.56K | $6.36M | $51.33K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.97% | 1.05% | 1.07% | 0.98% | 1.04% | 1.10% | 1.39% | 2.40% | 1.44% | 0.86% | 0.90% | 1.23% | 0.93% | 1.18% | 0.84% | 1.11% | 4.74% | 89.56% | 0.43% | 1.26% | 1.06% |
Karyopharm Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $35.40M, with a low forecast of $35.40M, and a high forecast of $35.40M. KPTI's average Quarter revenue forecast represents a -1.68% decrease compared to the company's last Quarter revenue of $36.01M (Sep 23).
Karyopharm Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-31.26M | $-29.57M | $-28.31M | $-32.55M | $-30.16M | $-42.48M | $-34.41M | $46.68M | $-43.51M | $-48.22M | $-51.94M | $-36.03M | $-46.41M | $-39.29M | $-46.11M | $-41.68M | $-38.01M | $-40.08M | $-62.91M | $-38.28M | $-29.71M |
| Avg Forecast | $-43.84M | $-41.52M | $-43.13M | $-39.89M | $-32.85M | $-32.16M | $-30.71M | $-41.01M | $-30.03M | $-31.61M | $-30.25M | $-37.28M | $-29.20M | $-29.54M | $-30.50M | $-39.87M | $-44.70M | $-22.23M | $-22.30M | $-47.55M | $-24.26M | $-19.52M | $-24.10M | $-40.10M | $-13.86M | $-2.35M | $-89.89K | $-47.00M | $-28.40M | $-27.94M |
| High Forecast | $-43.84M | $-41.52M | $-43.13M | $-39.89M | $-32.85M | $-28.83M | $-30.71M | $-32.80M | $-30.03M | $-31.61M | $-30.25M | $-29.82M | $-29.20M | $-29.54M | $-30.50M | $-31.90M | $-44.70M | $-22.23M | $-22.30M | $-38.04M | $-24.26M | $-19.52M | $-24.10M | $-32.08M | $-13.86M | $-2.35M | $-89.89K | $-37.60M | $-22.72M | $-22.35M |
| Low Forecast | $-43.84M | $-41.52M | $-43.13M | $-39.89M | $-32.85M | $-34.21M | $-30.71M | $-49.21M | $-30.03M | $-31.61M | $-30.25M | $-44.73M | $-29.20M | $-29.54M | $-30.50M | $-47.84M | $-44.70M | $-22.23M | $-22.30M | $-57.06M | $-24.26M | $-19.52M | $-24.10M | $-48.12M | $-13.86M | $-2.35M | $-89.89K | $-56.40M | $-34.08M | $-33.52M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.99% | 0.98% | 0.76% | 1.11% | 1.02% | 1.39% | 0.86% | -1.04% | 1.96% | 2.16% | 1.09% | 1.49% | 2.38% | 1.63% | 1.15% | 3.01% | 16.17% | 445.82% | 1.34% | 1.35% | 1.06% |
1 analysts predict KPTI's average Quarter EBITDA for Mar 22 to be $-39.87M, with a high of $-31.90M and a low of $-47.84M. This is -185.41% lower than Karyopharm Therapeutics's previous annual EBITDA (Dec 21) of $46.68M.
Karyopharm Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 12 |
| Net Income | - | - | - | - | - | - | - | - | - | $-34.51M | $-32.63M | $-34.13M | $-38.51M | $-36.32M | $-49.06M | $-41.40M | $38.72M | $-51.81M | $-53.58M | $-57.41M | $-43.42M | $-53.49M | $-46.43M | $-52.93M | $-48.65M | $-41.37M | $-43.41M | $-66.16M | $-38.46M | $-29.92M |
| Avg Forecast | $-24.71M | $-24.71M | $-21.62M | $-24.71M | $-37.81M | $-40.59M | $-46.00M | $-49.34M | $-47.87M | $-43.24M | $-52.85M | $-44.85M | $110.58M | $-87.34M | $-97.80M | $-47.97M | $-69.88M | $-103.98M | $-115.05M | $-52.56M | $-91.42M | $-108.56M | $-89.72M | $-46.03M | $-103.46M | $-127.59M | $-151.98M | $-49.43M | $-28.53M | $-28.13M |
| High Forecast | $-24.71M | $-24.71M | $-21.62M | $-24.71M | $-37.81M | $-25.56M | $-46.00M | $-39.47M | $-42.92M | $-43.24M | $-52.85M | $-35.88M | $132.69M | $-87.34M | $-97.80M | $-38.38M | $-69.88M | $-103.98M | $-115.05M | $-42.05M | $-91.42M | $-108.56M | $-89.72M | $-36.82M | $-103.46M | $-127.59M | $-151.98M | $-39.54M | $-22.83M | $-22.50M |
| Low Forecast | $-24.71M | $-24.71M | $-21.62M | $-24.71M | $-37.81M | $-51.12M | $-46.00M | $-59.20M | $-54.47M | $-43.24M | $-52.85M | $-53.82M | $88.46M | $-87.34M | $-97.80M | $-57.56M | $-69.88M | $-103.98M | $-115.05M | $-63.07M | $-91.42M | $-108.56M | $-89.72M | $-55.23M | $-103.46M | $-127.59M | $-151.98M | $-59.32M | $-34.24M | $-33.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.80% | 0.62% | 0.76% | -0.35% | 0.42% | 0.50% | 0.86% | -0.55% | 0.50% | 0.47% | 1.09% | 0.47% | 0.49% | 0.52% | 1.15% | 0.47% | 0.32% | 0.29% | 1.34% | 1.35% | 1.06% |
Karyopharm Therapeutics's average Quarter net income forecast for Mar 22 is $-47.97M, with a range of $-57.56M to $-38.38M. KPTI's average Quarter net income forecast represents a -223.89% decrease compared to the company's last Quarter net income of $38.72M (Dec 21).
Karyopharm Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 12 |
| SG&A | - | - | - | - | - | - | - | - | - | $30.80M | $34.48M | $35.91M | $34.65M | $34.65M | $37.34M | $38.77M | $34.56M | $35.10M | $36.53M | $37.65M | $33.93M | $30.97M | $30.84M | $30.68M | $28.39M | $25.27M | $24.66M | $27.10M | $7.62M | $6.26M |
| Avg Forecast | $64.74M | $61.31M | $63.69M | $58.90M | $48.51M | $47.50M | $45.35M | $43.18M | $44.34M | $46.68M | $44.67M | $45.48M | $43.12M | $43.62M | $45.04M | $43.09M | $66.02M | $32.83M | $32.94M | $32.43M | $35.83M | $28.83M | $35.58M | $26.88M | $20.46M | $3.47M | $132.75K | $456.56K | $5.65M | $80.36K |
| High Forecast | $64.74M | $61.31M | $63.69M | $58.90M | $48.51M | $50.52M | $45.35M | $43.18M | $44.34M | $46.68M | $44.67M | $45.48M | $43.12M | $43.62M | $45.04M | $43.09M | $66.02M | $32.83M | $32.94M | $32.43M | $35.83M | $28.83M | $35.58M | $26.88M | $20.46M | $3.47M | $132.75K | $456.56K | $6.79M | $96.43K |
| Low Forecast | $64.74M | $61.31M | $63.69M | $58.90M | $48.51M | $42.58M | $45.35M | $43.18M | $44.34M | $46.68M | $44.67M | $45.48M | $43.12M | $43.62M | $45.04M | $43.09M | $66.02M | $32.83M | $32.94M | $32.43M | $35.83M | $28.83M | $35.58M | $26.88M | $20.46M | $3.47M | $132.75K | $456.56K | $4.52M | $64.29K |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.66% | 0.77% | 0.79% | 0.80% | 0.79% | 0.83% | 0.90% | 0.52% | 1.07% | 1.11% | 1.16% | 0.95% | 1.07% | 0.87% | 1.14% | 1.39% | 7.28% | 185.77% | 59.36% | 1.35% | 77.95% |
Karyopharm Therapeutics's average Quarter SG&A projection for Dec 23 is $44.34M, based on 3 Wall Street analysts, with a range of $44.34M to $44.34M. The forecast indicates a 43.94% rise compared to KPTI last annual SG&A of $30.80M (Sep 23).
Karyopharm Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 12 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.30 | $-0.29 | $-0.30 | $-0.43 | $-0.45 | $-0.62 | $-0.53 | $0.51 | $-0.69 | $-0.71 | $-0.77 | $-0.59 | $-0.73 | $-0.63 | $-0.78 | $-0.76 | $-0.67 | $-0.71 | $-1.09 | $-0.78 | $-0.71 |
| Avg Forecast | $-0.16 | $-0.16 | $-0.14 | $-0.16 | $-0.24 | $-0.26 | $-0.30 | $-0.33 | $-0.31 | $-0.28 | $-0.34 | $-0.37 | $-0.35 | $-0.57 | $-0.63 | $-0.63 | $-0.45 | $-0.67 | $-0.74 | $-0.71 | $-0.59 | $-0.70 | $-0.58 | $-0.69 | $-0.67 | $-0.83 | $-0.98 | $-0.87 | $-0.46 | $-0.63 |
| High Forecast | $-0.16 | $-0.16 | $-0.14 | $-0.16 | $-0.24 | $-0.17 | $-0.30 | $-0.33 | $-0.28 | $-0.28 | $-0.34 | $-0.37 | $-0.35 | $-0.57 | $-0.63 | $-0.63 | $-0.45 | $-0.67 | $-0.74 | $-0.71 | $-0.59 | $-0.70 | $-0.58 | $-0.69 | $-0.67 | $-0.83 | $-0.98 | $-0.87 | $-0.37 | $-0.50 |
| Low Forecast | $-0.16 | $-0.16 | $-0.14 | $-0.16 | $-0.24 | $-0.33 | $-0.30 | $-0.33 | $-0.35 | $-0.28 | $-0.34 | $-0.37 | $-0.35 | $-0.57 | $-0.63 | $-0.63 | $-0.45 | $-0.67 | $-0.74 | $-0.71 | $-0.59 | $-0.70 | $-0.58 | $-0.69 | $-0.67 | $-0.83 | $-0.98 | $-0.87 | $-0.55 | $-0.76 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.07% | 0.85% | 0.82% | 1.22% | 0.80% | 0.98% | 0.84% | -1.13% | 1.02% | 0.95% | 1.09% | 1.00% | 1.04% | 1.08% | 1.12% | 1.13% | 0.81% | 0.72% | 1.25% | 1.70% | 1.13% |
According to 1 Wall Street analysts, Karyopharm Therapeutics's projected average Quarter EPS for Mar 22 is $-0.63, with a low estimate of $-0.63 and a high estimate of $-0.63. This represents a -223.73% decrease compared to KPTI previous annual EPS of $0.51 (Dec 21).
Karyopharm Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BLUE | bluebird bio | $0.46 | $14.13 | 2971.74% | Hold |
| PMVP | PMV Pharmaceuticals | $1.64 | $24.75 | 1409.15% | Buy |
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| KPTI | Karyopharm Therapeutics | $0.93 | $7.33 | 688.17% | Buy |
| XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
| CTMX | CytomX Therapeutics | $1.01 | $5.77 | 471.29% | Buy |
| GOSS | Gossamer Bio | $0.89 | $3.75 | 321.35% | Buy |
| NUVB | Nuvation Bio | $2.29 | $6.75 | 194.76% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.95 | $7.00 | 137.29% | Buy |
| ASMB | Assembly Biosciences | $16.98 | $35.50 | 109.07% | Buy |
| REPL | Replimune Group | $12.02 | $24.20 | 101.33% | Buy |
| LYRA | Lyra Therapeutics | $0.26 | $0.50 | 92.31% | Hold |
| MREO | Mereo BioPharma Group | $4.01 | $6.75 | 68.33% | Buy |
| MRSN | Mersana Therapeutics | $1.84 | $3.00 | 63.04% | Buy |
| AGIO | Agios Pharmaceuticals | $44.83 | $48.71 | 8.65% | Buy |
| HOOK | HOOKIPA Pharma | $3.76 | $3.00 | -20.21% | Buy |
KPTI Forecast FAQ
Is Karyopharm Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, Karyopharm Therapeutics (KPTI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of KPTI's total ratings.
What is KPTI's price target?
Karyopharm Therapeutics (KPTI) average price target is $7.33 with a range of $3 to $14, implying a 685.64% from its last price of $0.933. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Karyopharm Therapeutics stock go up soon?
According to Wall Street analysts' prediction for KPTI stock, the company can go up by 685.64% (from the last price of $0.933 to the average price target of $7.33), up by 1400.54% based on the highest stock price target, and up by 221.54% based on the lowest stock price target.
Can Karyopharm Therapeutics stock reach $1?
KPTI's average twelve months analyst stock price target of $7.33 supports the claim that Karyopharm Therapeutics can reach $1 in the near future.
What are Karyopharm Therapeutics's analysts' financial forecasts?
Karyopharm Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $147.35M (high $149.77M, low $143.42M), average EBITDA is $-137M (high $-125M, low $-147M), average net income is $-174M (high $-149M, low $-194M), average SG&A $184.54M (high $187.56M, low $179.62M), and average EPS is $-1.139 (high $-1.042, low $-1.208). KPTI's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $198.54M (high $198.54M, low $198.54M), average EBITDA is $-168M (high $-168M, low $-168M), average net income is $-95.744M (high $-95.744M, low $-95.744M), average SG&A $248.64M (high $248.64M, low $248.64M), and average EPS is $-0.62 (high $-0.62, low $-0.62).
Did the KPTI's actual financial results beat the analysts' financial forecasts?
Based on Karyopharm Therapeutics's last annual report (Dec 2023), the company's revenue was $146.03M, beating the average analysts forecast of $144.67M by 0.94%. Apple's EBITDA was $-130M, beating the average prediction of $-129M by 0.29%. The company's net income was $-143M, missing the average estimation of $-189M by -24.21%. Apple's SG&A was $131.88M, missing the average forecast of $181.18M by -27.21%. Lastly, the company's EPS was $-1.25, missing the average prediction of $-1.3 by -3.82%. In terms of the last quarterly report (Sep 2023), Karyopharm Therapeutics's revenue was $36.01M, missing the average analysts' forecast of $37.27M by -3.39%. The company's EBITDA was $-31.26M, missing the average prediction of $-31.608M by -1.10%. Karyopharm Therapeutics's net income was $-34.506M, missing the average estimation of $-43.239M by -20.20%. The company's SG&A was $30.8M, missing the average forecast of $46.68M by -34.01%. Lastly, the company's EPS was $-0.3, beating the average prediction of $-0.28 by 7.14%